頁籤選單縮合
題 名 | PD-1/PD-L1抑制劑治療三陰性乳癌=PD-1/PD-L1 Inhibitors to Treat Triple Negative Breast Cancer |
---|---|
作 者 | 楊慧心; 毛箴言; 陳琦華; 鄭吉元; | 書刊名 | 藥學雜誌 |
卷 期 | 35:4=141 2019.12[民108.12] |
頁 次 | 頁56-60 |
分類號 | 418.29 |
關鍵詞 | 三陰性乳癌; 免疫檢查點抑制劑; Triple negative breast cancer; Immune checkpoint inhibitor; |
語 文 | 中文(Chinese) |
中文摘要 | 乳癌患者之癌細胞在進行免疫組織化學染色法 (immunohistochemistry) 發現:雌 性素受體 (estrogen receptor)、黃體素受體 (progesterone receptor) 及人類表皮生長因子 第二型受體 (human epidermal growth factor receptor 2,HER2) 均呈現陰性 (negative) 者稱之為三陰性乳癌 (triple negative breast cancer,TNBC)。TNBC 佔乳癌的15-20%, 目前治療是以化療為主,但其療效並不理想,絕大多數的患者在治療後一至三年內 易發生復發及遠端轉移,因此,亟待新的治療方法。由於 PD-L1 免疫檢查點抑制劑 (immune checkpoint inhibitors,ICIs) atezolizumab 併用化療藥 nab-paclitaxel 的大型研 究結果已證實免疫療法可有效治療 TNBC,因此目前有許多臨床試驗是使用計劃性細 胞死亡蛋白質 (programmed cell death-1,PD-1) 及其配體 PD-L1 (programmed cell death ligand 1) 免疫檢查點抑制劑作為早期或是晚期轉移性 TNBC 的治療。本文將匯整這些 研究的結果及進行中的大型研究計畫。 |
英文摘要 | Based on the immunohistochemical staining, triple negative breast cancer (TNBC) is defined as breast tumors lacking expression of estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2. It accounts for approximately 15% to 20% of all breast cancers. Although TNBC is sensitive to chemotherapy, the overall outcomes of TNBC are worse than for other breast cancers. Additionally, this group is also known for an early peak of recurrence between the first and third year after diagnosis, and more aggressive metastases. Therefore, new treatment is urgently needed. Owing to the significantly positive results of large-scale study of atezolizumab, a PDL1 immune checkpoint inhibitor, in combination with the chemotherapy of nab-paclitaxel for the treatment of TNBC; hence, several clinical trials currently use PD-1/PD-L1 inhibitors for the treatment of early or metastatic TNBC. This article will summarize the results of these ongoing studies. |
本系統中英文摘要資訊取自各篇刊載內容。